ALAVERT D-12 HOUR OTC
Generic Name and Formulations:
Loratadine 5mg, pseudoephedrine sulfate 120mg; ext-rel tabs.
Indications for ALAVERT D-12 HOUR:
Seasonal allergic rhinitis with nasal congestion.
Swallow whole. 1 tab every 12 hrs.
Narrow-angle glaucoma. Urinary retention. Severe hypertension or coronary artery disease. During or within 14 days of MAOIs.
Hepatic or renal impairment. Hypertension. Ischemic heart disease. Increased intraocular pressure. Thyroid disease. GI or GU obstruction. Seizures. Diabetes. Pregnancy (Cat.B). Nursing mothers: not recommended.
See Contraindications. Pseudoephedrine: Antagonizes antihypertensives. Increased ectopic pacemaker activity with digitalis.
Antihistamine + sympathomimetic.
Dry mouth, insomnia, somnolence, nervousness, dizziness, dyspepsia, pharyngitis, anorexia, bronchospasm.
Loratadine: Hepatic (CYP3A4, 2D6); Pseudoephedrine: incompletely metabolized (less than 1%).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy